Home

Leqvio

Leqvio is a brand name for lecanemab-irmb, a monoclonal antibody designed for the treatment of Alzheimer's disease. It is developed by Eisai Inc. and BioNTech SE. The drug works by targeting and removing amyloid-beta protein, a key component of the plaques found in the brains of people with Alzheimer's disease. Leqvio is administered via subcutaneous injection, providing a convenient alternative to intravenous infusions.

The drug was approved by the U.S. Food and Drug Administration (FDA) in October 2023 for the

Leqvio is indicated for the treatment of Alzheimer's disease in adults with mild to moderate Alzheimer's disease,

The most common side effects of Leqvio include injection site reactions, headache, and nausea. Serious side

Leqvio is a significant advancement in the treatment of Alzheimer's disease, offering a new option for patients

treatment
of
Alzheimer's
disease
in
adults
with
mild
to
moderate
Alzheimer's
disease.
The
approval
was
based
on
data
from
the
Phase
3
LEAD
study,
which
showed
that
Leqvio
significantly
slowed
the
decline
in
cognitive
function
compared
to
placebo.
as
determined
by
a
clinical
assessment.
It
is
not
approved
for
the
treatment
of
mild
cognitive
impairment
or
other
neurodegenerative
disorders.
effects
may
include
an
increased
risk
of
infections,
including
pneumonia
and
sepsis,
and
an
increased
risk
of
stroke.
Patients
should
be
monitored
for
these
potential
side
effects
during
treatment.
and
their
caregivers.
However,
as
with
any
medication,
it
is
important
for
patients
to
discuss
the
potential
benefits
and
risks
with
their
healthcare
provider
before
starting
treatment.